Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axitinib in metastatic renal cell cancer
NCT00076011Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2003
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of axitinib in renal cell carcinoma (RCC), sponsored by Pfizer. Primary endpoint: Objective Response Rate up to 139 weeks. Started Oct 2003; status: completed.
02
Drugs
axitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00076011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076011.